Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 5-diethylaminoethyl-3-phenyl-1,2,4-oxadiazole
2. Bredon
3. Oxobron
4. Oxolamine Citrate
5. Oxolamine Monohydrochloride
1. 959-14-8
2. N,n-diethyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethanamine
3. Oxolamina
4. Oksalamin
5. 683 M
6. Af 438
7. Oxadiazole; 683m
8. 5-(2-diethylaminoethyl)-3-phenyl-1,2,4-oxadiazole
9. Af-438 Free Base
10. N,n-diethyl-3-phenyl-1,2,4-oxadiazole-5-ethanamine
11. 90bea145gy
12. Skf 9976 Free Base
13. Skf-9976 Free Base
14. Af-438 [as Citrate]
15. Oxolamine (inn)
16. Skf 9976 [as Citrate]
17. 5-(2-dietilaminoetil)-3-fenil-1,2,4-oxadiazolo
18. Oxolamine [inn]
19. Oxolev
20. Jatan
21. 1,2,4-oxadiazole, 5-(2-(diethylamino)ethyl)-3-phenyl-
22. Oxolev A
23. Ossolamina [dcit]
24. Oxolamina [italian]
25. Ossolamina
26. Oxolaminum
27. Oxolamine [inn:dcf]
28. N,n-diethyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethan-1-amine
29. Oxolaminum [inn-latin]
30. Oxolamina [inn-spanish]
31. Einecs 213-493-4
32. Brn 0527181
33. Unii-90bea145gy
34. Oksalamin (tn)
35. 3-phenyl-5-(beta-diethylaminoethyl)-1,2,4-oxodiazole
36. 5-(2-dietilaminoetil)-3-fenil-1,2,4-oxadiazolo [italian]
37. Oxolamine [mi]
38. Prestwick0_000826
39. Prestwick1_000826
40. Prestwick2_000826
41. Prestwick3_000826
42. Oxolamine [mart.]
43. Ec 213-493-4
44. Oxolamine [who-dd]
45. Bspbio_000751
46. Schembl893333
47. Spbio_002672
48. Bpbio1_000827
49. Zinc1874
50. 1,2,4-oxadiazole-5-ethanamine, N,n-diethyl-3-phenyl-
51. Chembl1620875
52. Dtxsid5023403
53. Chebi:94607
54. Db13216
55. Ncgc00179449-01
56. Sbi-0207016.p001
57. Ft-0748644
58. D07387
59. 959o148
60. Q576684
61. Brd-k42596464-048-03-6
62. 3-phenyl-5-(.beta.-diethylaminoethyl)-1,2,4-oxodiazole
63. N,n-diethyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethanamine 2-hydroxy-1,2,3-propanetricarboxylate
| Molecular Weight | 245.32 g/mol |
|---|---|
| Molecular Formula | C14H19N3O |
| XLogP3 | 2.9 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 6 |
| Exact Mass | 245.152812238 g/mol |
| Monoisotopic Mass | 245.152812238 g/mol |
| Topological Polar Surface Area | 42.2 Ų |
| Heavy Atom Count | 18 |
| Formal Charge | 0 |
| Complexity | 227 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antitussive Agents
Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally. (See all compounds classified as Antitussive Agents.)
R - Respiratory system
R05 - Cough and cold preparations
R05D - Cough suppressants, excl. combinations with expectorants
R05DB - Other cough suppressants
R05DB07 - Oxolamine
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Digital Content
NEWS #PharmaBuzz
Market Place
ABOUT THIS PAGE
17
PharmaCompass offers a list of Oxolamine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Oxolamine manufacturer or Oxolamine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Oxolamine manufacturer or Oxolamine supplier.
PharmaCompass also assists you with knowing the Oxolamine API Price utilized in the formulation of products. Oxolamine API Price is not always fixed or binding as the Oxolamine Price is obtained through a variety of data sources. The Oxolamine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Oxolamine Citrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Oxolamine Citrate, including repackagers and relabelers. The FDA regulates Oxolamine Citrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Oxolamine Citrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Oxolamine Citrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Oxolamine Citrate supplier is an individual or a company that provides Oxolamine Citrate active pharmaceutical ingredient (API) or Oxolamine Citrate finished formulations upon request. The Oxolamine Citrate suppliers may include Oxolamine Citrate API manufacturers, exporters, distributors and traders.
click here to find a list of Oxolamine Citrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Oxolamine Citrate written confirmation (Oxolamine Citrate WC) is an official document issued by a regulatory agency to a Oxolamine Citrate manufacturer, verifying that the manufacturing facility of a Oxolamine Citrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Oxolamine Citrate APIs or Oxolamine Citrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Oxolamine Citrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Oxolamine Citrate suppliers with Written Confirmation (WC) on PharmaCompass.
Oxolamine Citrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Oxolamine Citrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Oxolamine Citrate GMP manufacturer or Oxolamine Citrate GMP API supplier for your needs.
A Oxolamine Citrate CoA (Certificate of Analysis) is a formal document that attests to Oxolamine Citrate's compliance with Oxolamine Citrate specifications and serves as a tool for batch-level quality control.
Oxolamine Citrate CoA mostly includes findings from lab analyses of a specific batch. For each Oxolamine Citrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Oxolamine Citrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Oxolamine Citrate EP), Oxolamine Citrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Oxolamine Citrate USP).
